Global Cardiopulmonary Bypass Equipment Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, By Product Type (Single-Roller Pump CPB, Double-Roller Pump CPB, Centrifugal Pump CPB), By Application (Cardiac Surgery, Lung Transplant Operations, Acute Respiratory Failure, Others), By End User (Hospitals, Cardiac Surgery Centres, Ambulatory Surgical Centres), By Region, By Company 2021-2031F 2021-2031F

Key Insights	Details
Forecast Period	2026 - 2031
Market Size (2025)	USD 366.04 Million
CAGR (2026-2031)	4.05%
Fastest Growing Segment	Centrifugal systems (7.09% CAGR through 2031)
Largest Market	North America
Market Size (2031)	USD 464.5 Million

Market Overview

The Global Cardiopulmonary Bypass Equipment Market is expected to grow from USD 366.04 Million in 2025 to USD 464.5 Million by 2031 at a 4.05% CAGR. Cardiopulmonary bypass equipment, also known as a heart-lung machine, temporarily undertakes the physiological functions of the heart and lungs during cardiac surgery. This device oxygenates and circulates blood outside the body, providing surgeons with a motionless, blood-free surgical field to perform complex cardiovascular procedures. The market for this specialized technology is fundamentally supported by the rising global incidence of cardiovascular diseases, the expanding aging population, and continuous advancements in cardiac surgical techniques, including hybrid procedures that may integrate bypass technology.

The operational landscape underpinning this market is substantial; according to the American Board of Cardiovascular Perfusion (ABCP), in 2025, the organization projected reaching 5,000 active Certified Clinical Perfusionists (CCPs) worldwide, reflecting the dedicated professional workforce vital for administering cardiopulmonary bypass procedures. Despite these growth drivers, a significant challenge that could impede market expansion is the escalating cost associated with comprehensive research, development, and stringent regulatory approval processes for novel and existing medical devices.

Key Market Drivers

Rising Cardiovascular Disease Burden Drives CPB Demand
The rising global burden of cardiovascular diseases represents a fundamental driver for the cardiopulmonary bypass equipment market. The increasing prevalence and mortality rates associated with conditions such as coronary artery disease and valvular heart disease necessitate complex surgical interventions where heart-lung machines are essential. These procedures, which include coronary artery bypass grafting and heart valve repair or replacement, cannot typically be performed without temporarily taking over the functions of the heart and lungs. According to a study published in the European Journal of Preventive Cardiology in August 2025, an expected 20.5 million cardiovascular deaths are projected globally in 2025, highlighting the substantial disease burden requiring intervention. This significant number of severe cardiac cases underscores the continuous demand for cardiopulmonary bypass technology to facilitate life-saving operations.

Advances in CPB Technology Expand Market Adoption
Concurrently, advancements in cardiopulmonary bypass technology significantly contribute to market expansion by enhancing equipment safety, efficiency, and clinical utility. Innovations have led to the development of more compact, user-friendly, and biologically compatible systems, which improve patient outcomes and broaden the applicability of these devices. For example, LivaNova's Essenz Perfusion System represented approximately 55% of the company's annual heart-lung machine unit placements in 2025, indicating strong adoption of advanced equipment designed for improved performance. Furthermore, the ongoing development of integrated systems that provide real-time patient data and improved perfusion strategies allows for more tailored and effective surgical support. Reflecting the vitality of this sector, LivaNova reported that its full-year 2025 cardiopulmonary revenue reached $785 million, demonstrating considerable market activity and investment in this specialized equipment segment.

Download Free Sample Report

Key Market Challenges

Rising R&D and regulatory costs constrain market growth
The escalating cost associated with comprehensive research, development, and stringent regulatory approval processes significantly hampers the growth of the global cardiopulmonary bypass equipment market. This financial burden directly impacts manufacturers by demanding substantial upfront investment and prolonged timelines to bring novel and updated devices to market. Such high expenditures can deter smaller innovators and limit the frequency of product enhancements from established companies.

FDA PMA fees and testing costs raise development expenses and pricing
For instance, the regulatory pathway for complex medical devices like cardiopulmonary bypass equipment often necessitates Premarket Approval. According to the U.S. Food and Drug Administration's Medical Device User Fee rates, in Fiscal Year 2026, the standard fee for a Premarket Approval application was $579,272, reflecting an approximately 7.1 percent increase from the prior fiscal year. This substantial and increasing fee, coupled with extensive testing and clinical trial expenses, translates into higher overall development costs. Consequently, these elevated costs contribute to increased product pricing, which can restrict market adoption, particularly in cost-sensitive healthcare systems, thereby directly impeding overall market expansion for advanced cardiopulmonary bypass technologies.

Key Market Trends

AI-Driven Digital Monitoring Transforming Cardiopulmonary Bypass Perfusion
Integration of artificial intelligence and advanced digital monitoring is reshaping the global cardiopulmonary bypass equipment market by enabling more precise and adaptive perfusion strategies. Real-time analysis of patient physiological data, predictive analytics for potential complications, and automated adjustments to bypass parameters optimize patient management during complex cardiac procedures. The implementation of AI-driven systems promises to enhance clinical decision-making, thereby improving efficiency and reducing the cognitive load on perfusionists. According to a news release from Terumo Corporation, in October 2026, the company established a six-year strategic research collaboration with the University of Oxford, providing over $9 million USD of financial support to advance organ perfusion technologies. This investment highlights the commitment of key market players to integrating sophisticated digital capabilities into perfusion care.

Advances in Neuroprotection and Patient Safety Features
The development of enhanced neuroprotection and patient safety features represents another critical trend influencing the cardiopulmonary bypass equipment market, driven by the imperative to minimize post-operative complications and improve long-term patient outcomes. Innovations focus on maintaining cerebral perfusion, preventing microemboli, and mitigating inflammatory responses during bypass, which are crucial for reducing neurological and systemic adverse events. This drives demand for equipment with improved biocompatibility, advanced filtration, and precise temperature management capabilities. According to The Society of Thoracic Surgeons, in July 2026, its 2026 Clinical Practice Guidelines for the Prevention and Treatment of New-Onset Postoperative Atrial Fibrillation after Cardiac Surgery were published, addressing the most frequent complication following cardiac surgery. Such evolving clinical guidelines emphasize the ongoing need for advanced equipment that supports comprehensive patient safety protocols.

Segmental Insights

Centrifugal Bypass Systems: Fastest-Growing with Safety and Hemocompatibility Benefits
The key segmental insight for the Global Cardiopulmonary Bypass Equipment Market highlights centrifugal systems as the fastest-growing segment. This rapid expansion is primarily driven by their inherent advantages in patient safety and superior hemocompatibility compared to traditional alternatives. Centrifugal pumps minimize blood trauma, reduce hemolysis, and decrease the systemic inflammatory response during bypass procedures, contributing to improved postoperative patient outcomes such as shorter recovery times and reduced complication rates. Furthermore, ongoing technological advancements in pump design and integration, coupled with a growing clinical preference for systems that enhance procedural control and mitigate risks, are propelling the increased adoption of centrifugal bypass equipment in various cardiac interventions.

Regional Insights

North America Leads the Global Cardiopulmonary Bypass Equipment Market
North America consistently leads the global cardiopulmonary bypass equipment market due to its highly advanced healthcare infrastructure and numerous specialized cardiac surgery centers. The significant prevalence of cardiovascular diseases and an aging population in the region drive a substantial volume of complex cardiac procedures requiring such equipment. Furthermore, supportive reimbursement policies and considerable investments in research and development by key medical device manufacturers foster continuous technological advancements. The rigorous, yet clear, regulatory framework established by the U.S. Food and Drug Administration (FDA) also provides a structured environment for innovation and market entry, further solidifying North America's dominant position.

Recent Developments

• In August 2025, LivaNova PLC commenced the commercial launch of its Essenz™ Perfusion System in China, marking a strategic expansion into the world's second-largest market for heart-lung machines. The Essenz Perfusion System, which recently secured regulatory approval from China's National Medical Products Administration, provides a patient-tailored perfusion approach using data-driven decision-making. This system is engineered to enhance both clinical workflows and the quality of patient care during vital cardiopulmonary bypass procedures. Its introduction represents an advancement in extracorporeal circulation technology within the global cardiopulmonary bypass equipment sector.
• In February 2025, Getinge announced its plans to phase out its cardiopulmonary surgical perfusion product portfolio, including the HL 40 Heart-Lung Machine and HCU 40 heater-cooler unit, by the end of 2025. This strategic decision aimed to reallocate investments towards its extracorporeal membrane oxygenation (ECMO) and intra-aortic balloon pump offerings. The company cited a continuous decline in market share for its traditional cardiopulmonary bypass equipment since 2015 as a primary reason for this exit. This withdrawal of key products signifies a notable shift in the competitive landscape of the global cardiopulmonary bypass equipment market.
• In September 2024, Medtronic launched the VitalFlow™ Extracorporeal Membrane Oxygenation (ECMO) system, expanding its cardiac surgical and respiratory innovation portfolio. This new system, a significant advancement in life support technology, was designed to bridge the gap between bedside care and intra-hospital transport, offering a more streamlined and efficient ECMO experience. The VitalFlow system incorporates the Medtronic Nautilus ECMO oxygenator design and aims to address critical clinical needs in cardiopulmonary support by centralizing real-time performance data and offering enhanced configurability. This launch directly impacts the global cardiopulmonary bypass equipment market by introducing advanced ECMO capabilities.
• In January 2024, LivaNova PLC announced a strategic decision to wind down its Advanced Circulatory Support (ACS) business unit by the end of the year. This move was intended to concentrate the company's resources on its core cardiopulmonary and neuromodulation units. As part of this restructuring, LivaNova planned to integrate its standalone cannulae products and associated accessories, including the ProtekDuo, into its cardiopulmonary business unit portfolio. This strategic shift underscores the company's commitment to its primary cardiopulmonary offerings within the global cardiopulmonary bypass equipment market.

Key Market Players

• Boston Scientific Corporation
• Abbott Laboratories
• Gettinge AB
• Fresenius Medical Care
• Medtronic

By Product Type	By Application	By End User	By Region
Single-Roller Pump CPB Double-Roller Pump CPB Centrifugal Pump CPB	Cardiac Surgery Lung Transplant Operations Acute Respiratory Failure Others	Hospitals Cardiac Surgery Centres Ambulatory Surgical Centres	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Cardiopulmonary Bypass Equipment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Cardiopulmonary Bypass Equipment Market, By Product Type:

• Single-Roller Pump CPB
• Double-Roller Pump CPB
• Centrifugal Pump CPB

• Cardiopulmonary Bypass Equipment Market, By Application:

• Cardiac Surgery
• Lung Transplant Operations
• Acute Respiratory Failure
• Others

• Cardiopulmonary Bypass Equipment Market, By End User:

• Hospitals
• Cardiac Surgery Centres
• Ambulatory Surgical Centres

• Cardiopulmonary Bypass Equipment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE